Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03197064 · ClinicalTrials.gov registry record · Phase 4
Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia
A Phase 4 study of Postoperative Nausea, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT03197064 is a Phase 4 study of Postoperative Nausea that has completed, run by Stanford University. The registered enrollment target is 11 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03197064, a Phase 4 study of Postoperative Nausea, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if intravenous fosaprepitant can interfere with nervous system monitoring signals in patients having surgery under general anesthesia. This medication has numerous effects on the sensory nerve transmission which can theoretically have effects on the ability to accurately measure somatosensory evoked potentials.
Conditions Studied
Interventions
- DRUG Fosaprepitant 150 mg
Study Locations (1)
California
- Stanford University Medical Center - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2020-01-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03197064
The ClinicalTrials.gov registry entry for NCT03197064 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postoperative Nausea appearing as the primary indexed condition, and to 1 intervention - of which Fosaprepitant 150 mg is the first listed.
NCT03197064 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03197064 about?
NCT03197064 is a clinical study titled "Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia". The purpose of this study is to determine if intravenous fosaprepitant can interfere with nervous system monitoring signals in patients having surgery under general anesthesia. This medication has numerous effects on the sensory nerve transmission which can theoretically have effects on the ability ...
What is the current status of trial NCT03197064?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2018-01-01. Estimated completion is 2020-01-31.
What conditions does trial NCT03197064 study?
This clinical trial studies the following conditions: Postoperative Nausea.
What interventions are being tested in trial NCT03197064?
The interventions under investigation include: Fosaprepitant 150 mg (DRUG).
Who is sponsoring clinical trial NCT03197064?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03197064 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postoperative Nausea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.